Accès ouvert
2025
article
OpenAlex
Anthony F. Yu, Chau T. Dang, Chaya S. Moskowitz, Akriti Mishra Meza et autres
BACKGROUND: Echocardiograms are recommended every 3 months to monitor for cancer therapy-related cardiac dysfunction (CTRCD) among patients treated with HER2-targeted therapy, despite increasing use of safer regimens associated with low CTRCD risk. OBJECTIVES: This study evaluated the cardiac safety of reduced CTRCD …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Anthony F. Yu, Jessica M. Scott, Jessica Flynn, Chaya S. Moskowitz et autres
Abstract Aims Ventricular–arterial (VA) coupling and myocardial work can assess the interaction between the left ventricle and the arterial system and provide insight into cancer-therapy-related cardiac dysfunction (CTRCD). This study assessed the relationship between VA coupling and myocardial work indices with CTRCD …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Anthony F. Yu, Charlie White, Zhigang Zhang, Jennifer E. Liu et autres
Purpose Regional nodal irradiation (RNI) for breast cancer yields improvements in disease outcomes, yet comprehensive target coverage often increases cardiac radiation therapy (RT) dose. Volumetric modulated arc therapy (VMAT) may mitigate high-dose cardiac exposure, although it often increases the volume of low-dose …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Ioanna Kosmidou, Megan Durkin, Eileen Vella, Neisha DeJesus et autres
BACKGROUND: There is limited information on the prognostic impact of new onset versus preexistent atrial fibrillation (AF) in hospitalized patients with cancer. OBJECTIVES: We sought to determine the clinical impact of new onset AF (NOAF) compared with preexistent AF in hospitalized patients …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Raina Jain, Michael Park, Nicole Liberman, Hannah Agoglia et autres
Introduction: Cardiac MRI (CMR) is often used to identify thrombi (C THR ) based on absence of contrast enhancement but its utility as a predictor of therapeutic response of anticoagulation (AC) is unknown. Methods: Adult (≥18yo) pts with systemic cancer were matched …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Anthony F. Yu, I‐Hsin Lin, Justine Jorgensen, Robert S. Copeland-Halperin et autres
BACKGROUND: Cancer therapy-related cardiac dysfunction (CTRCD) is an important treatment-limiting toxicity for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that adversely affects cancer and cardiovascular outcomes. Easy-to-use tools that incorporate readily accessible clinical variables for individual estimation of …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Angel Chan, Tania Ruiz Maya, Christine Park, Katherine Tak et autres
us
(code pays fourni par la source)
Accès ouvert
2023
preprint
OpenAlex
Anthony F. Yu, Charlie White, Zhigang Zhang, Jennifer Liu et autres
Introduction: Regional nodal irradiation (RNI) for breast cancer yields improvements in disease outcomes, yet comprehensive target coverage often increases cardiac radiation (RT) dose. Volumetric modulated arc therapy (VMAT) may mitigate high-dose cardiac exposure, although often increases the volume of low-dose exposure. The …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Anthony F. Yu, Chau T. Dang, Justine Jorgensen, Chaya S. Moskowitz et autres
12083 Background: Non-anthracycline-based therapy is a treatment option for patients (pts) with HER2-positive breast cancer (BC) and is associated with lower risk of cancer therapy related cardiac dysfunction (CTRCD) compared to anthracycline-based treatment. Given the reduced CTRCD risk with non-anthracycline HER2-targeted therapies, …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Raina Jain, Nicole Liberman, Hannah Agoglia, Michael Park et autres
e24070 Background: Cardiac metastases (CMET) can occur in late-stage cancer, but limited data exists on prognostic implications in context of current day cancer care. Cardiac magnetic resonance imaging (CMR) provides a new, well validated, means to identify CMET in vivo, and assess …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Anthony F. Yu, Zachary Moore, Chaya S. Moskowitz, Jennifer E. Liu et autres
Importance: Cancer therapy-related cardiac dysfunction (CTRCD) is a potentially serious cardiotoxicity of treatments for ERBB2-positive breast cancer (formerly HER2). Identifying early biomarkers of cardiotoxicity could facilitate an individualized approach to cardiac surveillance and early pharmacologic intervention. Circulating cell-free DNA (cfDNA) of cardiomyocyte …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Syed Mahmood, Peter A. Riedell, Stephanie Feldman, Gina George et autres
AIMS: Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient's immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the association between CAR-T-related severe cardiovascular events (SCE) and mortality. METHODS AND RESULTS: …
us
(code pays fourni par la source)